Kinnate is a biopharmaceutical company advancing a pipeline of precision oncology therapeutics to treat patients with genomically. Founded in 2018, Kinnate Biopharma is backed by investors that include Eshelman Ventures, Foresite Capital, Nextech Invest, OrbiMed, and Vida Ventures and is headquartered in San Diego.